C-Type Natriuretic Peptide (CNP) (1-22), human

C-Type Natriuretic Peptide (CNP) (1-22), human is a synthetic peptide corresponding to the biologically active 22-amino acid form of human CNP. As a member of the natriuretic peptide family, CNP is structurally related to atrial and brain natriuretic peptides but exhibits unique receptor selectivity and physiological roles, particularly in vascular and skeletal tissues. Its primary mechanism involves binding to natriuretic peptide receptor-B (NPR-B), leading to the activation of intracellular cyclic guanosine monophosphate (cGMP) signaling pathways. Due to its distinct biological activities and regulatory functions, CNP (1-22) serves as a valuable research tool in studies of cardiovascular physiology, bone growth, and cellular signaling.

Signal transduction research: As a potent activator of NPR-B, CNP (1-22) is widely employed in dissecting cGMP-mediated signaling cascades. Researchers utilize it to investigate the downstream effects of natriuretic peptide receptor activation, including modulation of protein kinase G activity, ion channel function, and intracellular calcium dynamics. These studies are essential for elucidating the molecular mechanisms underlying vascular tone regulation, cellular proliferation, and tissue remodeling.

Vascular biology studies: The peptide is frequently used in experimental models to explore its vasorelaxant properties and its role in endothelial function. By inducing smooth muscle relaxation and influencing vascular permeability, CNP (1-22) enables detailed analysis of blood vessel physiology, endothelial signaling, and the interplay between natriuretic peptides and other vasoactive agents. Such applications are particularly valuable for understanding the regulation of blood pressure and the maintenance of vascular homeostasis.

Bone and cartilage research: CNP (1-22) has emerged as a key tool in studies of endochondral ossification and skeletal development. Its ability to stimulate chondrocyte proliferation and matrix production through NPR-B-mediated cGMP signaling provides insight into the molecular pathways governing bone growth and cartilage maintenance. Researchers use the peptide in vitro and in ex vivo tissue models to delineate the factors that influence longitudinal bone growth and to identify potential molecular targets for skeletal disorders.

Pharmacological profiling: The synthetic peptide is instrumental in receptor binding assays and functional studies aimed at characterizing NPR-B agonists and antagonists. By serving as a reference ligand, CNP (1-22) allows for the assessment of compound potency, receptor selectivity, and downstream signaling efficacy. Such profiling is critical in early-stage drug discovery efforts targeting the natriuretic peptide system for cardiovascular and metabolic research.

Peptide-based assay development: CNP (1-22) is incorporated into various bioanalytical platforms, including ELISAs, biosensors, and high-throughput screening assays designed to quantify natriuretic peptide activity or receptor engagement. Its defined sequence and robust biological activity make it an ideal standard for calibrating assays, validating detection systems, and supporting the development of new analytical methodologies for basic and translational research.

1. An Isolated TCR αβ Restricted by HLA-A* 02: 01/CT37 Peptide Redirecting CD8+ T Cells to Kill and Secrete IFN-γ in Response to Lung Adenocarcinoma Cell Lines

2. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment

3. Store-operated Ca2+ entry sustains the fertilization Ca2+ signal in pig eggs

4. C-peptide and its C-terminal fragments improve erythrocyte deformability in type 1 diabetes patients

5. Quantitative Analysis of Ligands Effects on Bioefficacy of Nanoemulsion encapsulating Depigmenting Active